A TET2 mutation test looks for acquired DNA changes in blood-forming cells. TET2 mutations are common in clonal hematopoiesis, a state in which one altered stem-cell population produces a larger-than-usual share of blood cells. They also occur in myelodysplastic syndromes, myeloproliferative neoplasms, chronic myelomonocytic leukemia, acute myeloid leukemia, and some lymphoid cancers. The same mutation can therefore appear in a healthy person, someone with unexplained low blood counts, or a person with an established malignancy.
A positive TET2 result does not diagnose blood cancer by itself. Interpretation requires the complete blood count, symptoms, blood smear, bone marrow findings when indicated, chromosome studies, other gene mutations, and the variant allele fraction. Testing may be performed on blood, bone marrow, or a broader myeloid panel. A low-level result can represent age-related clonal hematopoiesis, while a larger or genetically complex clone may carry more risk. Treatment targets the clinical condition, not the TET2 mutation alone. Many people with incidental clonal hematopoiesis need monitoring and cardiovascular risk management rather than chemotherapy.
- A TET2 mutation alone cannot distinguish clonal hematopoiesis from leukemia or another myeloid neoplasm.
- Variant allele fraction estimates clone size but is affected by sample composition, copy number, and assay sensitivity.
- CHIP generally means a myeloid-associated clone without unexplained cytopenia or a diagnosed blood cancer.
- CCUS combines persistent unexplained cytopenia with a somatic clone and carries more progression risk than CHIP.
- New or worsening anemia, low platelets, abnormal white counts, infections, bleeding, or constitutional symptoms need hematology evaluation.
Table of Contents
- What TET2 Does
- Why the Test Is Ordered
- Samples, Methods, and Variant Allele Fraction
- How to Interpret a Positive Result
- CHIP, CCUS, and Blood Cancer
- Clinical Risk and Follow-Up
- Negative, Uncertain, and Germline Results
- Next Steps and Common Mistakes
What TET2 Does
TET2 encodes an enzyme involved in DNA demethylation. It helps convert one modified form of cytosine into intermediates that allow cells to adjust gene activity. In blood-forming stem and progenitor cells, this epigenetic regulation supports normal self-renewal and differentiation.
Most clinically important TET2 mutations reduce or eliminate gene function. A stem cell carrying such a mutation may gain a competitive advantage and produce an expanding clone of descendants. The clone can remain stable for years, expand under inflammation or treatment stress, or acquire additional mutations that contribute to a myeloid neoplasm.
TET2 is not specific to one disease. It is one of the most frequently mutated genes in clonal hematopoiesis and appears across myeloid disorders. It can also occur in T-cell lymphomas and other hematologic conditions. The test result therefore identifies a molecular feature, not a complete diagnosis.
Many TET2 variants are acquired, or somatic. They are found in some blood cells but not every cell in the body and are not usually passed to children. Rare constitutional TET2 disorders exist, but they are clinically different and generally involve biallelic germline variants. An adult myeloid panel result should not automatically be called inherited.
The biological effect depends on the exact variant and whether one or both TET2 copies are affected in the clone. Truncating variants, splice variants, and damaging missense variants can reduce function. Two TET2 mutations may occur in the same clone or separate clones. A routine report may not be able to determine their phase without additional analysis.
TET2-driven clones can alter inflammatory signaling in monocytes and macrophages. This biology helps explain why clonal hematopoiesis is associated not only with blood-cancer risk but also with cardiovascular disease. Association does not mean every carrier will have a heart event, and TET2 testing is not currently a stand-alone cardiovascular screening test.
Why the Test Is Ordered
TET2 is usually analyzed as part of a multigene myeloid or hematologic malignancy panel rather than as a single-gene test. The order may be diagnostic, prognostic, or exploratory depending on the clinical setting.
Common reasons include:
- Persistent anemia, neutropenia, thrombocytopenia, or more than one low blood-cell line without a clear cause.
- Unexplained high white-cell, monocyte, platelet, or red-cell counts.
- Abnormal blood-cell morphology on a peripheral smear.
- Suspected myelodysplastic syndrome, myeloproliferative neoplasm, chronic myelomonocytic leukemia, or acute myeloid leukemia.
- Classification of a known blood cancer and assessment of co-mutations.
- Follow-up of an incidental mutation found during tumor sequencing or research testing.
- Evaluation after chemotherapy or radiation when persistent cytopenias raise concern for therapy-related disease.
- Investigation of clonal hematopoiesis before or after stem-cell transplantation or cellular therapy in selected settings.
The test should answer a defined question. In a patient with cytopenias, it may help show clonality, but marrow morphology and exclusion of nutritional, immune, infectious, medication-related, renal, liver, and other causes remain essential. In established leukemia, TET2 may contribute to classification or prognosis but often does not determine therapy alone.
TET2 can appear as an incidental result when a blood sample is used as the normal comparator for solid-tumor sequencing. It may also contaminate a plasma liquid biopsy because blood-cell DNA enters plasma. A TET2 variant in plasma may come from clonal hematopoiesis rather than the solid tumor. Paired white-blood-cell sequencing can clarify the source.
Testing asymptomatic people solely to look for CHIP is not standard population screening. There is no proven intervention that eliminates most incidental clones, and results can create uncertainty. Testing is more useful when it addresses abnormal counts, a known malignancy, donor assessment, or a research protocol with appropriate counseling.
The clinician should review prior blood counts over time. A stable mild anemia for ten years differs from rapidly falling counts over three months. Treatment history, tobacco exposure, inflammatory disease, infections, medications, and family history also shape interpretation.
Samples, Methods, and Variant Allele Fraction
Testing can use peripheral blood or bone marrow aspirate. Blood is often adequate when abnormal cells circulate or when evaluating clonal hematopoiesis. Bone marrow provides morphology, cellularity, blast percentage, iron staining, flow cytometry, and cytogenetic material in addition to DNA. The best sample depends on the diagnostic question.
Most laboratories use next-generation sequencing. A myeloid panel may assess dozens to hundreds of genes and detect single-nucleotide variants and small insertions or deletions. Some panels also assess copy-number changes and selected structural variants. TET2 is a large gene, so adequate coverage and validated bioinformatics are important.
The report commonly includes variant allele fraction, or VAF. A VAF of 10% means about 10% of sequence reads at that position carried the variant. In a simple diploid sample with a heterozygous mutation, that may correspond roughly to 20% of nucleated cells in the clone. The relationship is only an estimate because blood-cell mixtures, copy-number changes, loss of heterozygosity, sample purity, and technical bias affect the number.
VAF should not be treated as a cancer stage or a precise percentage of diseased cells. A small clone can be clinically important if it carries a high-risk combination, while a larger isolated TET2 clone may remain stable. Trends can be informative when the same validated assay is repeated, but small changes near the assay’s measurement variability may not be meaningful.
Assay sensitivity matters. Conventional clinical panels may reliably detect variants around 2% to 5% VAF, while specialized error-corrected assays can detect much smaller clones. The commonly used CHIP definition often uses a VAF threshold of at least 2%, partly because that was the sensitivity of early studies. Biology does not change abruptly at 2%.
A positive report should include the exact DNA and protein change, classification, VAF, coverage, and assay limitations. It should be interpreted alongside:
- Complete blood count and trend.
- Peripheral smear.
- Bone marrow morphology and blast percentage when performed.
- Flow cytometry.
- Karyotype and fluorescence in situ hybridization.
- Other mutations and their VAFs.
- Clinical history, exposures, and prior therapy.
A broad genetic panel can find co-mutations that change risk. For example, spliceosome genes, TP53, RUNX1, IDH1/2, ASXL1, and signaling-pathway genes may carry different implications. The pattern and number of abnormalities often matter more than TET2 alone.
How to Interpret a Positive Result
A positive TET2 result means the laboratory detected a reportable variant in the tested sample. The next question is which clinical category best fits the person.
Incidental clone with normal counts
When a somatic TET2 mutation is present without persistent unexplained cytopenia, dysplasia, or a diagnosed hematologic malignancy, it may represent clonal hematopoiesis of indeterminate potential, or CHIP. The person has a clone and a higher relative risk of future blood cancer than someone without CHIP, but the absolute annual risk for many carriers is still low.
The commonly quoted average progression risk for CHIP is roughly 0.5% to 1% per year, but risk is not uniform. Clone size, multiple mutations, mutation type, age, blood-count changes, and specific genes modify it. An isolated TET2 clone at modest VAF often carries less hematologic progression risk than clones with certain spliceosome or TP53 alterations, although individual assessment is required.
Persistent cytopenia with a clone
When a person has otherwise unexplained persistent cytopenia plus a myeloid-associated somatic mutation but does not meet criteria for a defined myeloid neoplasm, the term clonal cytopenia of undetermined significance, or CCUS, may apply. CCUS has a higher progression risk than CHIP, especially when the clone is large or genetically complex.
CCUS is a diagnosis of exclusion. Iron, vitamin B12, folate, kidney disease, inflammation, autoimmune conditions, medications, infection, bleeding, and other causes must be considered. A bone marrow examination is often needed to exclude myelodysplastic syndrome.
Established myeloid neoplasm
In MDS, CMML, MPN, or AML, the TET2 mutation becomes one piece of the disease profile. Diagnosis follows current classification criteria that integrate morphology, blast percentage, cytogenetics, and defining genetic abnormalities. TET2 alone is not usually disease-defining.
In CMML, TET2 mutations are common and often occur with SRSF2, ASXL1, or RAS-pathway changes. In MDS or AML, the co-mutation pattern and chromosome findings influence prognosis. In myeloproliferative neoplasms, a TET2 mutation may coexist with JAK2, CALR, or MPL and may have arisen before or after the main driver.
Possible treatment-related clone
Cancer therapy can select pre-existing clones. TET2 clones may expand after chemotherapy, radiation, transplantation, or immune stress, although TP53 and PPM1D are particularly associated with therapy selection. A mutation after treatment does not by itself prove therapy-related leukemia. Blood-count trends and marrow findings determine whether the person has clonal hematopoiesis, CCUS, or a neoplasm.
CHIP, CCUS, and Blood Cancer
These categories are related but not interchangeable.
| Category | Typical findings | Meaning |
|---|---|---|
| CHIP | Somatic myeloid-associated clone, no unexplained persistent cytopenia, no hematologic cancer | Risk marker that often needs periodic CBC monitoring rather than cancer treatment |
| CCUS | Persistent unexplained cytopenia plus a somatic clone, without diagnostic marrow criteria for a myeloid neoplasm | Higher progression risk; closer hematology follow-up is often appropriate |
| MDS | Cytopenia with qualifying dysplasia, blasts, cytogenetic, or genetic criteria | Defined myeloid neoplasm requiring risk-stratified management |
| CMML | Persistent monocytosis plus morphologic and molecular features after excluding other causes | Myelodysplastic/myeloproliferative neoplasm |
| AML | Qualifying blasts or disease-defining genetic lesion with clinical-pathologic correlation | Acute leukemia requiring prompt specialist treatment |
A person can move between categories over time. CHIP may remain unchanged, evolve into CCUS as counts fall, or acquire additional mutations and progress to a neoplasm. Many carriers never progress. Monitoring aims to identify meaningful change without treating a molecular result as inevitable leukemia.
Bone marrow biopsy is not automatically required for every incidental low-level TET2 mutation. It becomes more relevant with persistent cytopenia, rising counts, abnormal cells, macrocytosis without explanation, constitutional symptoms, increasing clone size, or high-risk co-mutations. The decision should be made by hematology.
TET2 mutations can also occur in lymphoid neoplasms, especially some T-cell lymphomas, and may be present in an ancestral stem-cell clone shared by myeloid and lymphoid cells. Diagnosis still depends on tissue pathology, immunophenotype, and disease-specific criteria.
A detected clone can complicate solid-tumor testing. TET2, DNMT3A, and ASXL1 variants found in plasma often originate from blood cells. Without matched leukocyte sequencing, a report may mistakenly list them as tumor mutations. Oncologists and molecular pathologists should review whether the variant fits the solid cancer and whether its VAF tracks with tumor fraction.
Clinical Risk and Follow-Up
Follow-up depends on the clinical category, clone features, and blood counts. There is no universal schedule for every TET2-positive person. A stable incidental clone with normal counts may need a CBC once or twice a year, while CCUS or changing counts may require more frequent review and bone marrow assessment.
Features associated with greater hematologic risk include:
- Larger clone size.
- More than one driver mutation.
- High-risk genes or mutation combinations.
- Persistent or worsening cytopenia.
- Macrocytosis or abnormal red-cell distribution.
- Rising white cells, monocytes, platelets, or blasts.
- Abnormal cytogenetics.
- Prior chemotherapy or radiation.
- A steadily increasing VAF on comparable testing.
Symptoms that warrant earlier evaluation include worsening fatigue, shortness of breath, recurrent infections, fevers, easy bruising, bleeding, night sweats, unintentional weight loss, bone pain, or abdominal fullness. These symptoms are not specific to leukemia, but they should not wait for the next routine visit when blood counts are abnormal.
Clonal hematopoiesis is associated with higher rates of atherosclerotic cardiovascular disease. TET2-related inflammatory signaling is one proposed mechanism. Current care generally focuses on established risk factors: blood pressure, cholesterol, diabetes, smoking, exercise, and weight. There is no standard recommendation to use chemotherapy, anti-inflammatory drugs, or mutation-directed treatment solely to eradicate an asymptomatic TET2 clone.
Patients with CHIP should tell clinicians before stem-cell donation or intensive cancer therapy because the result may affect donor selection or surveillance in some programs. Decisions are individualized; the presence of a small clone is not an automatic exclusion from every procedure.
Repeat sequencing is not needed at every CBC. It may be useful when counts change, new symptoms arise, a marrow is performed, or a clinical program uses molecular trends for risk assessment. Testing too frequently can detect small fluctuations that do not change management.
When a myeloid neoplasm is diagnosed, treatment depends on disease category and risk. Options can include observation, supportive care, growth factors, hypomethylating agents, targeted drugs for other mutations, chemotherapy, or stem-cell transplantation. TET2 status may inform research or response patterns, but there is no widely used TET2-specific drug that treats every TET2-mutated condition.
Negative, Uncertain, and Germline Results
A negative TET2 result means no reportable variant was found above the assay’s detection limit. It does not exclude a blood cancer. Many myeloid neoplasms do not have TET2 mutations, and diagnosis may rely on morphology, cytogenetics, or another gene.
A negative result can also miss a small clone below the limit of detection. The report should state sensitivity, specimen type, and coverage. Clinical findings take priority when counts or marrow are concerning.
A VUS is a DNA change whose significance is unresolved. It should not be counted as a definitive clonal driver for diagnosis unless current disease criteria and expert laboratory interpretation support that use. Some hematology reports list only pathogenic or likely pathogenic somatic variants, while others include selected VUS findings. The classification policy should be clear.
Because TET2 mutations in blood are usually somatic, the VAF can resemble a germline heterozygous result near 50%, especially when the clone is large. Germline origin should be considered when the variant, age, phenotype, and family history suggest it, but blood or saliva may be unsuitable for confirmation because both contain hematopoietic cells. Cultured skin fibroblasts or another nonhematopoietic tissue may be needed.
Rare inherited TET2 deficiency is not the same as ordinary CHIP. It can involve immune dysregulation and childhood-onset hematologic disease. A specialist genetics evaluation is appropriate when the presentation is unusual, variants are biallelic, or there is a suggestive family pattern.
A report may later be updated as variant databases and disease classifications change. Keeping the original result and the testing laboratory’s contact information allows reinterpretation.
Next Steps and Common Mistakes
The first step after a positive result is to classify the person, not just the variant. Useful questions are:
- Why was testing ordered, and is there a persistent blood-count abnormality?
- What is the exact TET2 variant and VAF?
- Are there additional mutations or chromosome abnormalities?
- Was the sample blood, marrow, plasma, or tumor tissue?
- Does marrow morphology meet criteria for a defined neoplasm?
- Could the finding represent CHIP, CCUS, treatment-selected clonal hematopoiesis, or contamination of a solid-tumor assay?
- What CBC and clinical follow-up schedule is appropriate?
- What change would trigger repeat sequencing or bone marrow biopsy?
Common mistakes include calling every TET2 mutation leukemia, ignoring cytopenias because the clone seems small, and using VAF as a direct measure of cancer burden. Another mistake is attributing a plasma TET2 variant to a solid tumor without considering clonal hematopoiesis.
Patients should keep a table of CBC values over time rather than focus on one test. Hemoglobin, mean corpuscular volume, neutrophils, monocytes, platelets, and any circulating blasts can reveal a pattern. The laboratory reference range, symptoms, and trend are more informative than an isolated result.
A hematologist should coordinate unexplained cytopenia or a complex clone. Primary care can help manage cardiovascular risk and ensure that new symptoms are assessed. Oncology, transplant teams, molecular pathology, and genetics may join when the result arose during cancer care or possible germline disease is suspected.
The most accurate interpretation combines molecular evidence with the cells themselves. TET2 testing is valuable because it reveals clonality and biology, but it becomes clinically meaningful only when integrated with blood counts, morphology, cytogenetics, and the person’s course.
A single stable TET2 clone in a person with normal blood counts is not managed like acute leukemia. The reason for testing, clone size, count trends, symptoms, and co-mutations determine whether observation, additional marrow evaluation, or treatment is appropriate.
References
- TET2 mutation as Prototypic Clonal Hematopoiesis Lesion 2024 (Review)
- Clonal hematopoiesis and hematological malignancy 2024 (Review)
- International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data 2022 (Consensus Classification)
- Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms 2023 (Review)
- Clonal Hematopoiesis: Impact on Health and Disease 2025 (Review)
- What’s new in hematopathology 2025: myeloid neoplasms in the WHO 5th edition and ICC 2025 (Review)
Disclaimer
A TET2 mutation must be interpreted by a hematology team with blood counts, morphology, cytogenetics, co-mutations, and clinical history. This article is educational and does not diagnose CHIP, CCUS, or blood cancer; urgent symptoms or rapidly changing counts require prompt medical assessment.
